Pharma BD Deal Intelligence
On October 19, 2026 METiS TechBio announced a strategic collaboration with Eli Lilly and Company to co-develop next-generation lipid nanoparticle delivery platforms with improved tissue-specific targeting. METiS applies AiLNP, its AI-driven ionizable lipid discovery and optimization platform - described as a de novo lipid generation system combining a large lipid library, end-to-end screening and a lipid language model - while Lilly contributes drug discovery, development and commercialization capability. METiS is eligible for an upfront payment in the low double-digit millions of dollars, up to approximately $1.1 billion in development, regulatory and commercial milestones, and single-digit tiered royalties on annual net sales of resulting products. No specific therapeutic targets or indications were disclosed.